Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Development of a 3D printable maxillofacial silicone: Part II. Optimization of moderator and thixotropic agent.

Jindal SK, Sherriff M, Waters MG, Smay JE, Coward TJ.

J Prosthet Dent. 2018 Feb;119(2):299-304. doi: 10.1016/j.prosdent.2017.04.028. Epub 2017 Jun 20.

PMID:
28645662
2.

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.

Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lenaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Pérez-Herrán E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6271-80. doi: 10.1128/AAC.01339-16. Print 2016 Oct.

3.

Development of a 3D printable maxillofacial silicone: Part I. Optimization of polydimethylsiloxane chains and cross-linker concentration.

Jindal SK, Sherriff M, Waters MG, Coward TJ.

J Prosthet Dent. 2016 Oct;116(4):617-622. doi: 10.1016/j.prosdent.2016.02.020. Epub 2016 May 4.

PMID:
27158034
4.

Biocide activity against urinary catheter pathogens.

Malic S, Jordan RP, Waters MG, Stickler DJ, Williams DW.

Antimicrob Agents Chemother. 2014;58(2):1192-4. doi: 10.1128/AAC.01106-13. Epub 2013 Nov 18.

5.

Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis.

Strack AM, Carballo-Jane E, Wang SP, Xue J, Ping X, McNamara LA, Thankappan A, Price O, Wolff M, Wu TJ, Kawka D, Mariano M, Burton C, Chang CH, Chen J, Menke J, Luell S, Zycband EI, Tong X, Raubertas R, Sparrow CP, Hubbard B, Woods J, O'Neill G, Waters MG, Sitlani A.

J Lipid Res. 2013 Jan;54(1):177-88. doi: 10.1194/jlr.M031344. Epub 2012 Oct 28.

6.

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A.

Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877.

7.

(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.

Boatman PD, Lauring B, Schrader TO, Kasem M, Johnson BR, Skinner P, Jung JK, Xu J, Cherrier MC, Webb PJ, Semple G, Sage CR, Knudsen J, Chen R, Luo WL, Caro L, Cote J, Lai E, Wagner J, Taggart AK, Carballo-Jane E, Hammond M, Colletti SL, Tata JR, Connolly DT, Waters MG, Richman JG.

J Med Chem. 2012 Apr 26;55(8):3644-66. doi: 10.1021/jm2010964. Epub 2012 Apr 9.

PMID:
22435740
8.

Development of an "early warning" sensor for encrustation of urinary catheters following Proteus infection.

Malic S, Waters MG, Basil L, Stickler DJ, Williams DW.

J Biomed Mater Res B Appl Biomater. 2012 Jan;100(1):133-7. doi: 10.1002/jbm.b.31930. Epub 2011 Sep 27.

PMID:
21954120
9.

The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties.

Imbriglio JE, DiRocco D, Bodner R, Raghavan S, Chen W, Marley D, Esser C, Holt TG, Wolff MS, Taggart AK, Waters MG, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2011 May 1;21(9):2721-4. doi: 10.1016/j.bmcl.2010.11.116. Epub 2010 Dec 4.

PMID:
21185185
10.

Pharmacological activation and genetic manipulation of cystathionine beta-synthase alter circulating levels of homocysteine and hydrogen sulfide in mice.

Jensen KK, Geoghagen NS, Jin L, Holt TG, Luo Q, Malkowitz L, Ni W, Quan S, Waters MG, Zhang A, Zhou HH, Cheng K, Luo MJ.

Eur J Pharmacol. 2011 Jan 10;650(1):86-93. doi: 10.1016/j.ejphar.2010.09.080. Epub 2010 Oct 15.

PMID:
20955694
11.

GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.

Imbriglio JE, Chang S, Liang R, Raghavan S, Schmidt D, Smenton A, Tria S, Schrader TO, Jung JK, Esser C, Holt TG, Wolff MS, Taggart AK, Cheng K, Carballo-Jane E, Waters MG, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4. doi: 10.1016/j.bmcl.2010.06.041. Epub 2010 Jun 10.

PMID:
20615702
12.

Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.

Ding FX, Shen HC, Wilsie LC, Krsmanovic ML, Taggart AK, Ren N, Cai TQ, Wang J, Tong X, Holt TG, Chen Q, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3372-5. doi: 10.1016/j.bmcl.2010.04.013. Epub 2010 Apr 11.

PMID:
20452209
13.

Anthranilic acid replacements in a niacin receptor agonist.

Schmidt D, Smenton A, Raghavan S, Shen H, Ding FX, Carballo-Jane E, Luell S, Ciecko T, Holt TG, Wolff M, Taggart A, Wilsie L, Krsmanovic M, Ren N, Blom D, Cheng K, McCann PE, Waters MG, Tata J, Colletti S.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3426-30. doi: 10.1016/j.bmcl.2010.04.001. Epub 2010 Apr 8.

PMID:
20444602
14.

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.

Shen HC, Ding FX, Raghavan S, Deng Q, Luell S, Forrest MJ, Carballo-Jane E, Wilsie LC, Krsmanovic ML, Taggart AK, Wu KK, Wu TJ, Cheng K, Ren N, Cai TQ, Chen Q, Wang J, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2010 Mar 25;53(6):2666-70. doi: 10.1021/jm100022r.

PMID:
20184326
15.

Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.

Shen HC, Ding FX, Deng Q, Wilsie LC, Krsmanovic ML, Taggart AK, Carballo-Jane E, Ren N, Cai TQ, Wu TJ, Wu KK, Cheng K, Chen Q, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2009 Apr 23;52(8):2587-602. doi: 10.1021/jm900151e.

PMID:
19309152
16.

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.

Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Norquist JM, Lai E, Waters MG, Kuznetsova O, Sisk CM, Mitchel YB.

Cardiol Clin. 2008 Nov;26(4):547-60. Review.

PMID:
19031552
17.

Role of GPR81 in lactate-mediated reduction of adipose lipolysis.

Cai TQ, Ren N, Jin L, Cheng K, Kash S, Chen R, Wright SD, Taggart AK, Waters MG.

Biochem Biophys Res Commun. 2008 Dec 19;377(3):987-91. doi: 10.1016/j.bbrc.2008.10.088. Epub 2008 Oct 24.

PMID:
18952058
18.

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans.

Lai E, Waters MG, Tata JR, Radziszewski W, Perevozskaya I, Zheng W, Wenning L, Connolly DT, Semple G, Johnson-Levonas AO, Wagner JA, Mitchel Y, Paolini JF.

J Clin Lipidol. 2008 Oct;2(5):375-83. doi: 10.1016/j.jacl.2008.08.445. Epub 2008 Aug 23.

PMID:
21291763
19.

Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.

Deng Q, Frie JL, Marley DM, Beresis RT, Ren N, Cai TQ, Taggart AK, Cheng K, Carballo-Jane E, Wang J, Tong X, Waters MG, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2008 Sep 15;18(18):4963-7. doi: 10.1016/j.bmcl.2008.08.030. Epub 2008 Aug 14.

PMID:
18760600
20.

Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A.

Shen HC, Taggart AK, Wilsie LC, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2008 Sep 15;18(18):4948-51. doi: 10.1016/j.bmcl.2008.08.039. Epub 2008 Aug 14.

PMID:
18752940
21.

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.

Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, Cherrier MC, Webb PJ, Tamura SY, Boatman PD, Sage CR, Schrader TO, Chen R, Colletti SL, Tata JR, Waters MG, Cheng K, Taggart AK, Cai TQ, Carballo-Jane E, Behan DP, Connolly DT, Richman JG.

J Med Chem. 2008 Aug 28;51(16):5101-8. doi: 10.1021/jm800258p. Epub 2008 Jul 30.

PMID:
18665582
22.

Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.

Raghavan S, Tria GS, Shen HC, Ding FX, Taggart AK, Ren N, Wilsie LC, Krsmanovic ML, Holt TG, Wolff MS, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3163-7. doi: 10.1016/j.bmcl.2008.04.071. Epub 2008 May 1.

PMID:
18477506
23.

Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A.

Shen HC, Szymonifka MJ, Kharbanda D, Deng Q, Carballo-Jane E, Wu KK, Wu TJ, Cheng K, Ren N, Cai TQ, Taggart AK, Wang J, Tong X, Waters MG, Hammond ML, Tata JR, Colletti SL.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6723-8. Epub 2007 Oct 18.

PMID:
18029181
24.

Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor.

Shen HC, Ding FX, Luell S, Forrest MJ, Carballo-Jane E, Wu KK, Wu TJ, Cheng K, Wilsie LC, Krsmanovic ML, Taggart AK, Ren N, Cai TQ, Deng Q, Chen Q, Wang J, Wolff MS, Tong X, Holt TG, Waters MG, Hammond ML, Tata JR, Colletti SL.

J Med Chem. 2007 Dec 13;50(25):6303-6. Epub 2007 Nov 10.

PMID:
17994679
25.

Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.

Carballo-Jane E, Gerckens LS, Luell S, Parlapiano AS, Wolff M, Colletti SL, Tata JR, Taggart AK, Waters MG, Richman JG, McCann ME, Forrest MJ.

J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):308-16. Epub 2007 Jun 23.

PMID:
17643322
26.

Potential role for epidermal Langerhans cells in nicotinic acid-induced vasodilatation in the mouse.

Carballo-Jane E, Ciecko T, Luell S, Woods JW, Zycband EI, Waters MG, Forrest MJ.

Inflamm Res. 2007 Jun;56(6):254-61.

PMID:
17607550
27.

Nicotinic acid receptor agonists differentially activate downstream effectors.

Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Cham L, Maciejewski-Lenoir D, Behan DP, Boatman D, Chen R, Skinner P, Ornelas P, Waters MG, Wright SD, Semple G, Connolly DT.

J Biol Chem. 2007 Jun 22;282(25):18028-36. Epub 2007 Apr 23.

28.

Analysis of rheological properties of bone cements.

Nicholas MK, Waters MG, Holford KM, Adusei G.

J Mater Sci Mater Med. 2007 Jul;18(7):1407-12. Epub 2007 Feb 3.

PMID:
17277981
29.

Titanium surface modification and its effect on the adherence of Porphyromonas gingivalis: an in vitro study.

Amoroso PF, Adams RJ, Waters MG, Williams DW.

Clin Oral Implants Res. 2006 Dec;17(6):633-7. Erratum in: Clin Oral Implants Res. 2009 Jun;20(6):643. Pier-Francesco, Amoroso [corrected to Amoroso, Pier Francesco].

PMID:
17092220
30.

A clinical assessment of the performance of a sensor to detect crystalline biofilm formation on indwelling bladder catheters.

Stickler DJ, Jones SM, Adusei GO, Waters MG, Cloete J, Mathur S, Feneley RC.

BJU Int. 2006 Dec;98(6):1244-9. Epub 2006 Oct 9.

31.

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, Waters MG.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6682-7. Epub 2006 Apr 14.

32.
33.

Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.

Wu KK, Wu TJ, Chin J, Mitnaul LJ, Hernandez M, Cai TQ, Ren N, Waters MG, Wright SD, Cheng K.

Atherosclerosis. 2005 Aug;181(2):251-9. Epub 2005 Feb 24.

PMID:
16039278
34.

Dsl1p, Tip20p, and the novel Dsl3(Sec39) protein are required for the stability of the Q/t-SNARE complex at the endoplasmic reticulum in yeast.

Kraynack BA, Chan A, Rosenthal E, Essid M, Umansky B, Waters MG, Schmitt HD.

Mol Biol Cell. 2005 Sep;16(9):3963-77. Epub 2005 Jun 15. Erratum in: Mol Biol Cell. 2006 Jun;17(6):2853.

35.

(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.

Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, Connolly D, Offermanns S, Wright SD, Waters MG.

J Biol Chem. 2005 Jul 22;280(29):26649-52. Epub 2005 Jun 1.

36.

Reduced adherence of Candida to silane-treated silicone rubber.

Price CL, Williams DW, Waters MG, Coulthwaite L, Verran J, Taylor RL, Stickler D, Lewis MA.

J Biomed Mater Res B Appl Biomater. 2005 Jul;74(1):481-7.

PMID:
15906392
37.

Designing a prosthesis to simulate the elastic properties of skin.

Bellamy KE, Waters MG.

Biomed Mater Eng. 2005;15(1-2):21-7.

PMID:
15623927
38.

An elastomeric material for facial prostheses: synthesis, experimental and numerical testing aspects.

Bellamy K, Limbert G, Waters MG, Middleton J.

Biomaterials. 2003 Dec;24(27):5061-6.

PMID:
14559020
39.

Regulation of the angiopoietin-like protein 3 gene by LXR.

Kaplan R, Zhang T, Hernandez M, Gan FX, Wright SD, Waters MG, Cai TQ.

J Lipid Res. 2003 Jan;44(1):136-43.

40.

Characterization of a mammalian Golgi-localized protein complex, COG, that is required for normal Golgi morphology and function.

Ungar D, Oka T, Brittle EE, Vasile E, Lupashin VV, Chatterton JE, Heuser JE, Krieger M, Waters MG.

J Cell Biol. 2002 Apr 29;157(3):405-15. Epub 2002 Apr 29.

41.

Surface modification of an experimental silicone rubber aimed at reducing initial candidal adhesion.

Price C, Waters MG, Williams DW, Lewis MA, Stickler D.

J Biomed Mater Res. 2002;63(2):122-8.

PMID:
11870644
42.
43.
44.

Wettability of denture materials.

Zissis A, Yannikakis S, Jagger RG, Waters MG.

Quintessence Int. 2001 Jun;32(6):457-62.

PMID:
11491625
45.

Wettability of visible light-curing denture lining materials.

Zissis AJ, Polyzois GL, Jagger RG, Waters MG.

Int J Prosthodont. 2001 May-Jun;14(3):250-4.

PMID:
11484573
46.

Dsl1p, an essential protein required for membrane traffic at the endoplasmic reticulum/Golgi interface in yeast.

Vanrheenen SM, Reilly BA, Chamberlain SJ, Waters MG.

Traffic. 2001 Mar;2(3):212-31.

47.

Membrane tethering and fusion in the secretory and endocytic pathways.

Waters MG, Hughson FM.

Traffic. 2000 Aug;1(8):588-97. Review.

48.

Cell biology. ER-to-Golgi traffic--this bud's for you.

Brittle EE, Waters MG.

Science. 2000 Jul 21;289(5478):403-4.

PMID:
10939952
49.

Phosphorylation of the vesicle-tethering protein p115 by a casein kinase II-like enzyme is required for Golgi reassembly from isolated mitotic fragments.

Dirac-Svejstrup AB, Shorter J, Waters MG, Warren G.

J Cell Biol. 2000 Aug 7;150(3):475-88. Erratum in: J Cell Biol 2000 Aug 21;150(4):following 936.

50.

Interstitial cystitis: a retrospective analysis of treatment with pentosan polysulfate and follow-up patient survey.

Waters MG, Suleskey JF, Finkelstein LJ, Van Overbeke ME, Zizza VJ, Stommel M.

J Am Osteopath Assoc. 2000 Mar;100(3 Suppl):S13-8.

PMID:
10763313

Supplemental Content

Loading ...
Support Center